Skip to main content
. 2020 May 8;11:658. doi: 10.3389/fphar.2020.00658

Figure 1.

Figure 1

The classification of the most common drugs used for the clinical treatment of LUTS/BPH, showing α1-blockers (α1 adrenergic antagonists), 5α-reductase inhibitors (5-ARIs), muscarinic receptor antagonists (MRAS), β3-adrenoceptor agonists (beta-3 agonists), and phosphodiesterase 5 inhibitors (PDE5Is).